Imaging scan using 18F-G1 to study immunotherapy in several cancers
Studies a 18F-G1 PET scan in adults with solid tumors or blood cancers receiving immunotherapy.
Plain-language title generated from the registry record
Registry title: The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07039474, who can take part
Where in China
- Peking University First HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT07039474
- Record updated
- 28 September 2026
- Original description
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapyRead full original descriptionShow less
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy
Inclusion: Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team; Subjects didn't receive previous immunotherapy; There exists at least one measurable target lesion according to the RECIST 1.1; ECOG performance status≤2; The expected survival time is ≥6 months; Effective contraceptive measures will be adopted during the study period and within 6 months after the study; Willing and able to fully understand and sign the informed consent form.
Exclusion: Receiving radiotherapy or interventional therapy during the immunotherapy; 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days; Combined with other malignant tumor; Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy; Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency; Women in the preconception period, pregnancy, or lactation period.